Alzheimer’s disease in Poland: early diagnosis, symptomatic treatment, and challenges ahead of the anti-amyloid therapy era Case report
Article Sidebar
Published:
Mar 1, 2026
Keywords:
Alzheimer’s disease, Alzheimer’s dementia, mild cognitive impairment, MCI, early diagnosis, prodromal symptoms, episodic memory, biomarkers
Main Article Content
Abstract
Introduction: Alzheimer’s disease accounts for 60–70% of dementia cases and affects approximately 500,000 Poles. Between 1992 and 2021, there was a global increase in cases by 141%. Long asymptomatic periods (15–20 years) and prodromal symptoms complicate early diagnosis.
Objective: To present diagnostics, symptomatic treatment, and challenges in Poland, based on a clinical case report.
Conclusions: Early diagnosis (interview + screening tests) is crucial before the introduction of anti-amyloid therapies. Barriers: stigma and low awareness. Recommended: public education and prioritizing biomarker testing.
Article Details
How to Cite
Filipek-Gliszczyńska, A. (2026). Alzheimer’s disease in Poland: early diagnosis, symptomatic treatment, and challenges ahead of the anti-amyloid therapy era. Medycyna Faktow (J EBM), 19(4(69), 578-581. https://doi.org/10.24292/01.MF.0425.14
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020; 25(24):5789. http://doi.org/10.3390/molecules25245789.
2. Knopman DS, Amieva H, Petersen RC et al. Alzheimer Disease. Nat Rev Dis Primers. 2021; 7(1):33. http://doi.org/10.1038/s41572-021-00269-y.
3. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment Approaches. Molecules. 2020; 25(24): 5789. http://doi.org/10.3390/molecules25245789.
4. Qin R, Zhao H, Gao H et al. Global trends in Alzheimer’s disease and other dementias: A comprehensive analysis of incidence, socio-demographic variations, and future projections. PLoS One. 2025; 20(12): e0338018. http://doi.org/10.1371/journal.pone.0338018.
5. Chen Y, Al-Nusaif M, Li S et al. Progress on early diagnosing Alzheimer’s disease. Front Med (Lausanne). 2024; 18(3): 446-64. http://doi.org/10.1007/s11684-023-1047-1.
6. Jack CR Jr, Bennett DA, Blennow K et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018; 14(4): 535-62. http://doi.org/10.1016/j.jalz.2018.02.018.
7. Kumar A, Sidhu J, Lui F et al. Alzheimer Disease. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) 2025 Jan.
8. Doody RS. Current treatments for Alzheimer’s disease: cholinesterase inhibitors. J Clin Psychiatry. 2003: 64 Suppl 9: 11-7.
9. Birks JS. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006; (1): CD005593. http://doi.org/10.1002/14651858.CD005593.
2. Knopman DS, Amieva H, Petersen RC et al. Alzheimer Disease. Nat Rev Dis Primers. 2021; 7(1):33. http://doi.org/10.1038/s41572-021-00269-y.
3. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment Approaches. Molecules. 2020; 25(24): 5789. http://doi.org/10.3390/molecules25245789.
4. Qin R, Zhao H, Gao H et al. Global trends in Alzheimer’s disease and other dementias: A comprehensive analysis of incidence, socio-demographic variations, and future projections. PLoS One. 2025; 20(12): e0338018. http://doi.org/10.1371/journal.pone.0338018.
5. Chen Y, Al-Nusaif M, Li S et al. Progress on early diagnosing Alzheimer’s disease. Front Med (Lausanne). 2024; 18(3): 446-64. http://doi.org/10.1007/s11684-023-1047-1.
6. Jack CR Jr, Bennett DA, Blennow K et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018; 14(4): 535-62. http://doi.org/10.1016/j.jalz.2018.02.018.
7. Kumar A, Sidhu J, Lui F et al. Alzheimer Disease. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) 2025 Jan.
8. Doody RS. Current treatments for Alzheimer’s disease: cholinesterase inhibitors. J Clin Psychiatry. 2003: 64 Suppl 9: 11-7.
9. Birks JS. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006; (1): CD005593. http://doi.org/10.1002/14651858.CD005593.